All In Biotech

Drug Trial Radar · NCT04630366

A Phase 1, First Time in Humans Study of NST-1024

A Phase 1, First Time in Man Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NST-1024 in Healthy Subjects and Otherwise Healthy Subjects With Elevated Triglycerides

Last checked: Nov 19, 2026Latest source record: Dec 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

96

Actual

Start

Oct 27, 2020

Primary completion

Jun 20, 2022

Study completion Jun 20, 2022

Sponsor

Lead sponsor
NorthSea Therapeutics B.V.Industry
Sponsor type
Industry
First posted
Nov 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A first time in man study of NST-1024

Conditions

  • Hypertriglyceridemia

Interventions

  • NST-1024Drug

    NST-1024

  • PlaceboDrug

    Matching placebo to NST-1024

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Leeds Clinical Research Unit

    Leeds, West Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.